Dendritic cells: A novel therapeutic modality

Annals of Oncology

Volumn 10, Issue 1, 1999, Pages 21-27

  Luykx De Bakker, S A ^a   De Gruijl, T D ^a   Scheper, R J ^a   Wagstaff, J ^b   Pinedo, H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Immunotherapy

Indexed keywords

ANTIGEN PRESENTING CELL; BONE MARROW CELL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS;

EID: 0033040442     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008349920664     Document Type: Review

References (90)

1. Steinman RM, Colin ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 1142-622.
2. Hart DN, McKenzie JL. Interstitial dendritic cells. Ann Rev Immunol 1990; 9: 271-96.
3. Matzinger P, Tolerance, danger and the extended family. Ann Rev Immunol 1994; 12: 991-1045.
4. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991; 9: 271-966.
5. Inaba K. Inaba M, Deguchi M et al. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci USA 1998; 90: 3038-40.
6. Reid CDI, Fryer PR, Clifford C et al. Identification of hematologic progenitors of macrophages and dendritic cell Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 1990; 76: 1139-49.
7. Reid CDI, Stackpool A, Meager A, Tikerpac J. Interaction of tumour necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992; 149: 2681-8.
8. Caux C, Dezutter-Dambuyant C, Schmitt D et al. GM-CSF and TF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-61.
9. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-6.
10. Saunders d, Lukas K, Ismaili J et al. Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte-macrophage colony stimulating factor. J Lxp Med 1996; 184: 2185-96.
11. Morse MA, Lyerly HK, Gilboa E et al. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res 1998; 58: 2965-8.
12. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
13. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alfa. J Exp Med 1994; 179: 1109-18.
14. Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996: 196: 137-51.
15. Zhou LJ, Tedder TF. CDI4+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sei USA 1996; 93: 2588-92.
16. Maraskovsky E, Brasel K, Teepe M et al. Dramatic increase in the number of functionally mature dendritic cells in Flt3 lidand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-62.
17. Siena S, Di Nicola M, Bregni M et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hetnatol 1995; 23: 1463-71.
18. Caux C, Vanbervliet B, Massacrier C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNFa. J Exp Med 1996; 184: 695-706.
19. Rosenzwajg M, Canque B, Gluckman JC. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood 1996; 87: 535-44.
20. Metcalf D, Shortman K, Vremec D et al. Effect of excess GM-CSF levels on hematopoiesis and leukemia development in GM-CSF/max 41 double transgenic mice. Leukemia 1996; 10: 713-9.
21. Steinman RM, Dendritic cells and immune-based therapies. Exp Hematol 1996; 24: 859-62.
22. Mackensen A, Herbst B, Kohler G et al. Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood 1995; 86: 2699-707.
23. Sallusto F, Cella M, Danielli C et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389-400.
24. Zitvogel L, Regnald A, Lozier A et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nature Med 1998; 4: 595-600.
25. Engering AJ, Cella M, Fluitsma DM et al. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv Exp Med 1997; 417: 183-7.
26. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17: 131-7.
27. Shen Z, Reznikoff G, Dranoff G et al. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158: 2723-30.
28. Roake JA, Rao AS, Morris PJ et al. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 1995; 181: 2237-47.
29. Pinedo HM, Giaccone G. P-glycoprotein: A marker of cancer-cell behavior. N Engl J Med 1995; 333: 1417-9.
30. Randolph GJ, Bealieu S, Pope M et al. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc Natl Acad Sci USA 1998; 95: 6924-9.
31. Marland G, Bakker AB, Adema GJ, Figdor CG. Dendritic cells in immune response induction. Stem Cells 1996; 14: 501-7.
32. Schoenberger SP, Toes REM, van der Voort EIH et al. T-cell help for cyloloxic T lymphocytes is mediated by CD40 CD40L interactions. Nature 1998; 393: 480-3.
33. Koppi TA, Tough-Bement T, Lewinsohn DM et al. CD40 ligand inhibits Fas CD95-mediated apoptosis of human blood-derived dendritic cells. Eur J Immunol 1997; 27: 3161-5.
34. Cella M, Scheidegger D, Palmer Lehmann K et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T T help via APC activation. J Exp Med 1996; 184: 747-52.
35. Heuller C, Koch F, Stanzl U et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26: 659-68.
36. Bennett SRM, Carbone FR, Karamalis F et al Help for cytotoxic-T-cell responses is mediated by DC40 signalling. Nature 1998; 393: 478-80.
37. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper abd T-killer cell. Nature 1998; 393: 474-8.
38. Winzler C, Rovere P, Rescigno M et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997; 185: 317-28.
39. Winzler C, Rovere P, Zimmermann VS et al. Checkpoints and functional stages in DC maturation. Adv Exp Med 1997; 417: 59-64.
40. Ludewig B, Graf D, Gelderblom HE. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP(CD40-ligand) and TNF-α, but strongly enhanced by interleukin-10. Eur J Immunol 1995; 25: 1943-50.
41. Thomas R, Lipsky PE, Dendritic cells: Origin and differentiation. Stem Cells 1996; 14: 196-206.
42. Inoue K, Furihata M, Ohtsuki Y et al. Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tomour progression and prognosis. Virchows Arch A 1993; 422: 351-5.
43. Gallo O, Bianchi S, Giannini A et al. Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngoscope 1991; 101: 487-93.
44. Meahara Y, Tomisaki S, Oda S et al. Lymph node metastasis and relation to tumour growth potential and local immune response in advanced gastric carcinoma. Int J Cancer 1997; 74: 224-8.
45. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993; 25: 338-43.
46. Tsujitani S, Oka A, Kondo A et al. Infiltration of dendritic cells into regional lymph nodes in gastric cancer. Cancer 1995; 75: 1478-83.
47. Tsujitani S, Kakeji Y, Watanabe A et al. Infitration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 199; 66: 2012-6.
48. Kerrebijn JD, Balm AJM, Knegt PP et al. Macrophage and dendritic cells in head and neck squamous-cell carcinoma: An immunohistochemical study. Cancer Immunol Immunother 1994; 38: 31-7.
49. NakanoT, Oka K, Takashashi T et al. Roles of Langerhans'cells and T-lymphocytes infiltrating cancer tissues in patients treated by radiation therapy for cervical cancer. Cancer 1992; 70: 2839-44.
50. Furihata M, Ohtsuki Y, Iwata J et al. HLA-DR antigen-and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma; their distribution in relation to prognosis. Virchows Archiv B Cell Pathol 1992; 61: 409-14.
51. Gabrilovich DI, Corak J, Ciernik IF et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997; 3:483-490.
52. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 1996; 2: 1096-103.
53. Chouaib S, Asselin-Paturel C, Mami-Chouaib F et al. The host-tumor immune conflict: From immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-7.
54. Morel A, Quarantino S, Douek DC et al. Split activity of interleukin-10 on antigen cature and antigen presentation by human dendritic cells: Definition of a maturative step. Eur J Immunol 1997; 27: 26-34.
55. Enk AH, Jonuleit H, Saloga J et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997; 73: 309-16.
56. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183-7.
57. Song W, Kong H, Carpenter H et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and terapeutic antitumor immunity. J Exp Med 1997; 186: 1247-56.
58. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Detective antigen presentation in tumor-bearing hosts. Cell Immunol 1996; 25: 101-10.
59. Gong J, Chen D, Kashiwaba M et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med 1997; 3: 558-611.
60. Specht JM, Wang G, Do MT et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997; 186: 1213-21.
61. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15: 94-103.
62. Strunk D, Rappersberger K, Egger C et al. Generation of human dendritic cells Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 1996; 87: 1292-302.
63. Bender A, Sapp G, Schuler G et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196: 121-35.
64. Bello-Fernandez C, Matyash M, Strobl H et al. Efficient retrovirus-mediaTed gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions. Hum Gene Ther 1997; 8: 1651-8.
65. Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-422.
66. Rosenberg SA, Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 1996; 88: 1635-44.
67. Boon T, van de Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183: 725-9.
68. Disis ML, Smith JW, Murphy AE et al. In vitro generation of human cytolylic T cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 1998; 54: 1071-6.
69. de Gruijl TD, Bantkes HJ, Walboomers JMM et al. Diflerential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitidinal study. Cancer Res 1998; 58: 1700-6.
70. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumours with tumor peptide-pulsed dendritic cells: Dependence on T-cells. B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
71. Gilboa E, Nair SK, Kim Lyerly H. Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82-7.
72. Nair SK, Boczkowski D, Snyder G, Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 1997; 27: 589-97.
73. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-32.
74. Reeves ME, Royal RE, Lam JS et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56: 5672-7.
75. Henderson RA, Nimgaonkar MT, Watkins SC et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-I). Cancer Res 1996; 56: 3763-70.
76. Tuting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 21: 2702-7.
77. Aicher A, Westermann J, Cayeux S et al. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells. Exp Hematol 1997; 25: 39-44.
78. Gong J, Chen L, Chen D et al. Induction of antigen-specitic antitumor immunity with adenovirus-transduced dendritic cells. GeneTher 1997; 4: 1023-8.
79. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to kuman dendritic cells. Blood 1998; 91: 392-8.
80. Arthur JF, Butterfield LH, Roth MD et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
81. Mulders P, Pang S, Dannull J et al. Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates. Cancer Res 1998; 58: 956-61.
82. Hsu FJ, Benike C, Hagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-88.
83. Gjertsen MK, Bakka A, Breiwik J et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995; 346: 1399-400.
84. Murphy G, Tjoa B, Ragde H et al. Phase 1 clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-80.
85. Hart DN, Clark GJ, Dekker JW et al. Dendritic cell surface molecules. A proliferating field. Adv Fxp Med 1997; 417: 439-42.
86. Savary CA, Grazziutti ML, Melichar B et al. Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients. Cancer Immunol Immunother 1998; 45: 234-40.
87. Triozzi PL, Aldrich W. Phenotypic and functional differences between human dendritic cells derived in vitro from hematopoietic progenitors and from monocytes macrophages. J Leukoc Biol 1997; 61: 600-8.
88. Fearnley DB, McLellan AD, Mannering SI et al. Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: Implications for studies on antigen-presenting cell function and immunotherapy. Blood 1997; 89: 3708-16.
89. Thomas R, Davis LS, Lipsky PE. Isolation and characterization of human peripheral blood dendritic cells. J Immunol 1993; 150: 821-34.
90. Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets. J Immunol 1994; 153: 4016-28.